Wire Stories
-
598ENHERTU� Reduced the Risk of Disease Progression or Death by 50% vs. Chemotherapy in Patients with HER2 Low Metastatic Breast Cancer with HR Positive and HR Negative Disease
Daiichi Sankyo and AstraZeneca�s ENHERTU also improved median overall survival by more than 6 months vs. chemotherapy in all patients evaluated in...
-
580
MEI Pharma and Kyowa Kirin Report New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2022
� Zandelisib Demonstrated 70.3% Objective Response Rate and 35.2% Complete Response Rate � � 87.5% of Responses Achieved in First Two Cycles...
-
517
Cubic Technology Launched to Provide Easier Rail Journeys for Queensland Commuters
Cubic Transportation Systems launches the first credit card and smart device-compatible gates on Queensland’s Heavy Rail Network, giving more payment options to...
-
510Kite Realty Group Trust to Present at NAREIT�s REITweek: 2022 Investor Conference
INDIANAPOLIS, June 03, 2022 (GLOBE NEWSWIRE) — Kite Realty Group Trust (NYSE: KRG) announced today that it will present at Nareit�s REITweek:...
-
463
Global Commercial Vehicle Surround View System Markets, 2021-2030: Revenue, Trends, Growth Opportunities, Competition, End Cases – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Commercial Vehicle Surround View System Market – Revenue, Trends, Growth Opportunities, Competition, COVID-19 Strategies, Regional Analysis and Future Outlook to...
-
484Zai Lab and Novocure Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer
Confirmed objective response rate was 50% for patients treated with TTFields together with standard-of-care chemotherapy Duration of response was 10.3 months One-year...
-
490
Patritumab Deruxtecan Continues to Show Promising Clinical Activity in Patients Across Subtypes of Metastatic Breast or Lung Cancer
Data from a phase 1/2 trial in patients with several subtypes of HER3 expressing metastatic breast cancer featured as oral presentation at...
-
506
Novocure and Zai Lab Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer
Confirmed objective response rate was 50% for patients treated with TTFields together with standard-of-care chemotherapy Duration of response was 10.3 months One-year...
-
476
Patritumab Deruxtecan Continues to Show Promising Clinical Activity in Patients Across Subtypes of Metastatic Breast or Lung Cancer
Data from a phase 1/2 trial in patients with several subtypes of HER3 expressing metastatic breast cancer featured as oral presentation at...
-
569
OliX Pharmaceuticals Announces Completion of Enrollment in Phase 2 Clinical Trial of OLX101A in Patients with Hypertrophic Scars
SUWON, South Korea–(BUSINESS WIRE)–#ClinicalTrial—OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced the completion of patient enrollment in...
